The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).
 
Jian Zhang
No Relationships to Disclose
 
Yanchun Meng
No Relationships to Disclose
 
Biyun Wang
No Relationships to Disclose
 
Xinhong Wu
No Relationships to Disclose
 
Hongmei Zheng
No Relationships to Disclose
 
Li Cai
No Relationships to Disclose
 
Wenyan Chen
No Relationships to Disclose
 
Leiping Wang
No Relationships to Disclose
 
Jun Cao
No Relationships to Disclose
 
Zhonghua Tao
No Relationships to Disclose
 
Ting Li
No Relationships to Disclose
 
Ni Sujie
No Relationships to Disclose
 
Zhengyan Yu
No Relationships to Disclose
 
XueSong Chen
No Relationships to Disclose
 
Qiang Peng
No Relationships to Disclose
 
Xin Hu
No Relationships to Disclose
 
Wenqing Yao
Employment - Jiangsu Hengrui Medicine
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca